Cargando…
mRNA as a medicine in nephrology: the future is now
The successful employment of messenger RNA (mRNA) as vaccine therapy for the prevention of COVID-19 infection has spotlighted the attention of scientific community onto the potential clinical application of these molecules as innovative and alternative therapeutic approaches in different fields of m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689145/ https://www.ncbi.nlm.nih.gov/pubmed/38046026 http://dx.doi.org/10.1093/ckj/sfad196 |
_version_ | 1785152310313222144 |
---|---|
author | Granata, Simona Stallone, Giovanni Zaza, Gianluigi |
author_facet | Granata, Simona Stallone, Giovanni Zaza, Gianluigi |
author_sort | Granata, Simona |
collection | PubMed |
description | The successful employment of messenger RNA (mRNA) as vaccine therapy for the prevention of COVID-19 infection has spotlighted the attention of scientific community onto the potential clinical application of these molecules as innovative and alternative therapeutic approaches in different fields of medicine. As therapy, mRNAs may be advantageous due to their unique biological properties of targeting almost any genetic component within the cell, many of which may be unreachable using other pharmacological/therapeutic approaches, and encoding any proteins and peptides without the need for their transport into the nuclei of the target cells. Additionally, these molecules may be rapidly designed/produced and clinically tested. Once the chemistry of the RNA and its delivery system are optimized, the cost of developing novel variants of these medications for new selected clinical disorders is significantly reduced. However, although potentially useful as new therapeutic weapons against several kidney diseases, the complex architecture of kidney and the inability of nanoparticles that accommodate oligonucleotides to cross the integral glomerular filtration barrier have largely decreased their potential employment in nephrology. However, in the next few years, the technical improvements in mRNA that increase translational efficiency, modulate innate and adaptive immunogenicity, and increase their delivery at the site of action will overcome these limitations. Therefore, this review has the scope of summarizing the key strengths of these RNA-based therapies and illustrating potential future directions and challenges of this promising technology for widespread therapeutic use in nephrology. |
format | Online Article Text |
id | pubmed-10689145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106891452023-12-02 mRNA as a medicine in nephrology: the future is now Granata, Simona Stallone, Giovanni Zaza, Gianluigi Clin Kidney J CKJ Review The successful employment of messenger RNA (mRNA) as vaccine therapy for the prevention of COVID-19 infection has spotlighted the attention of scientific community onto the potential clinical application of these molecules as innovative and alternative therapeutic approaches in different fields of medicine. As therapy, mRNAs may be advantageous due to their unique biological properties of targeting almost any genetic component within the cell, many of which may be unreachable using other pharmacological/therapeutic approaches, and encoding any proteins and peptides without the need for their transport into the nuclei of the target cells. Additionally, these molecules may be rapidly designed/produced and clinically tested. Once the chemistry of the RNA and its delivery system are optimized, the cost of developing novel variants of these medications for new selected clinical disorders is significantly reduced. However, although potentially useful as new therapeutic weapons against several kidney diseases, the complex architecture of kidney and the inability of nanoparticles that accommodate oligonucleotides to cross the integral glomerular filtration barrier have largely decreased their potential employment in nephrology. However, in the next few years, the technical improvements in mRNA that increase translational efficiency, modulate innate and adaptive immunogenicity, and increase their delivery at the site of action will overcome these limitations. Therefore, this review has the scope of summarizing the key strengths of these RNA-based therapies and illustrating potential future directions and challenges of this promising technology for widespread therapeutic use in nephrology. Oxford University Press 2023-08-17 /pmc/articles/PMC10689145/ /pubmed/38046026 http://dx.doi.org/10.1093/ckj/sfad196 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | CKJ Review Granata, Simona Stallone, Giovanni Zaza, Gianluigi mRNA as a medicine in nephrology: the future is now |
title | mRNA as a medicine in nephrology: the future is now |
title_full | mRNA as a medicine in nephrology: the future is now |
title_fullStr | mRNA as a medicine in nephrology: the future is now |
title_full_unstemmed | mRNA as a medicine in nephrology: the future is now |
title_short | mRNA as a medicine in nephrology: the future is now |
title_sort | mrna as a medicine in nephrology: the future is now |
topic | CKJ Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689145/ https://www.ncbi.nlm.nih.gov/pubmed/38046026 http://dx.doi.org/10.1093/ckj/sfad196 |
work_keys_str_mv | AT granatasimona mrnaasamedicineinnephrologythefutureisnow AT stallonegiovanni mrnaasamedicineinnephrologythefutureisnow AT zazagianluigi mrnaasamedicineinnephrologythefutureisnow |